GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET)

Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET) explained in plain language.

Never miss a new study

Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET) trials appear

Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Radiation drug trial offers hope for advanced gut cancer patients

Disease control Recruiting now

This study is testing whether adding a targeted radiation drug to standard hormone therapy works better than hormone therapy alone for newly diagnosed advanced neuroendocrine tumors of the gut and pancreas. The trial will enroll 240 patients with high disease burden to see if the…

Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET)

Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET)

Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR (GEP-NET) trials appear

Radiation drug trial offers hope for advanced gut cancer patients